imiquimod has been researched along with Carcinoma, Lewis Lung in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, M; Hijikata, Y; Inoue, H; Inoue, M; Inoue, T; Matsumura, Y; Miura, Y; Miyamoto, S; Nakanishi, Y; Narusawa, M; Okazaki, T; Sakamoto, C; Takahashi, A; Takayama, K; Tanaka, Y; Tani, K; Watanabe, A | 1 |
1 other study(ies) available for imiquimod and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Topics: Aminoquinolines; Animals; Antigens, CD; Cancer Vaccines; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Female; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Imiquimod; Immunotherapy; Interferon Inducers; Interferon Type I; Membrane Glycoproteins; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Receptor, Interferon alpha-beta; Sendai virus; Toll-Like Receptor 7; Transfection; Up-Regulation | 2014 |